Sign in

CIK 0001576885 · <br>Emerging growth company

Acumen Pharmaceuticals, Inc.

Sign in to watch
Ticker
ABOS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364108129
Phone
617-344-4190
Business address
1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Planned sale President and CEO sold 15,200 shares at $3.47 ($52,753)
  11. 4 Planned sale Chief Legal Officer & Corp Sec sold 8,933 shares at $3.48 ($31,048)
  12. 4 Planned sale CFO & Chief Business Officer sold 4,242 shares at $3.71 ($15,717)
  13. 4 Planned sale Chief Medical Officer sold 3,124 shares at $3.71 ($11,604)
  14. 4 Planned sale Chief Operating Officer sold 2,833 shares at $3.73 ($10,555)
  15. 4 Grant or award Chief Operating Officer acquired 73,000 shares (grant or award)
  16. 4 Grant or award Chief Legal Officer & Corp Sec acquired 91,000 shares (grant or award)
  17. 4 Grant or award Chief Medical Officer acquired 94,000 shares (grant or award)
  18. 4 Grant or award CFO & Chief Business Officer acquired 106,000 shares (grant or award)
  19. 4 Grant or award President and CEO acquired 401,000 shares (grant or award)
  20. 4 Planned sale Director sold 41,949 shares at an average $6.49 ($272,334)

Page 4 of 7 · 140 filings